Identification of first in class small molecule GFRAL blockers for the prevention and reversal of Cancer Anorexia-Cachexia
Identification of first in class small molecule GFRAL blockers for the prevention and reversal of Cancer Anorexia-Cachexia
批准号:
10091640
负责人:
Margaret Jackson
金额:
$5.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-11 至 2020-08-31
关键词:
AddressAdvanced Malignant NeoplasmAffectAgonistAnorexiaAntibodiesBindingBiologicalBiological AssayBody Weight decreasedBrainBrain StemCachexiaCancer EtiologyCancer ModelCancer PatientCatabolismChemicalsChemistryClinicalClinical TrialsDevelopmentDiseaseDiversity LibraryDoseDrug KineticsExhibitsFamilyFatty acid glycerol estersFormulationG-Protein-Coupled ReceptorsGDF15 geneGDNF receptorsGoalsGrantHumanIn VitroInvestigational DrugsKnock-in MouseKnowledgeLeadLibrariesLifeLigandsLuciferasesMalignant NeoplasmsMediatingMedicalMetabolismModelingMusOperative Surgical ProceduresOralOutcomePathway interactionsPatientsPharmaceutical ChemistryPharmacologyPharmacotherapyPhasePlasmaPositioning AttributePreventionPrimatesProbabilityRadiation therapyRattusReportingRiskRiversRouteRunningSafetySeriesSkeletal MuscleStructureSymptomsTestingTimeTimeLineTransfectionTumor BurdenTumor-DerivedXenograft Modelanalogappetite lossbasecancer anorexiacancer cachexiacancer therapychemotherapyclinical candidatecomputational chemistrycostcytokinedesignglial cell-line derived neurotrophic factorhigh throughput screeningin silicoin vivoin vivo Modelincreased appetiteinnovationinsightlead optimizationmortalitymuscle formnovelpatient stratificationpre-clinicalprecision medicinepreventreceptorreceptor bindingscreeningsmall moleculesuccesstreatment durationvirtualvirtual screening
中文摘要
项目摘要
该项目的目标是首次确定一种脑穿透性小分子拮抗剂
胶质细胞源性神经营养因子家族受体α样受体的预防和逆转
癌症厌食症-恶病质。厌食症-恶病质是一种虚弱的、危及生命的疾病,与
明显丧失食欲、骨骼肌和脂肪量。癌症厌食症-恶病质是主要的
未得到满足的医疗需求,80%的晚期癌症患者表现出恶病质,20%的癌症患者与癌症相关
死亡率来自恶病质,而不是直接的肿瘤负担。患者较难耐受
放射治疗、化疗、药物治疗和手术。因此,患者接受的剂量较低,
缩短治疗时间或不符合治疗条件,间接降低存活率。的确有
目前没有批准治疗厌食症-恶病质,因此有很高的未得到满足的医疗需求。
癌症厌食症-恶病质的病因归因于肿瘤引起的代谢异常。
衍生的细胞因子。恶病质前期和恶病质患者的生长分化水平较高
与生存不良相关的因子-15(GDF-15)。GDF-15已成为调解的关键因素
厌食症-恶病质。临床前,GDF-15在阻断时会引起小鼠、大鼠和灵长类动物的厌食症
内源性GDF-15在癌症恶病质模型中预防和逆转厌食症-恶病质
令人印象深刻的100%存活率。
最近,人们发现GDF-15通过位于
脑干。用小分子比生物阻断GDF-15的作用效果最好
有机会进入大脑,并达到足够的浓度,以阻止>;90%的GFRL。BYO质量
在我们的协助下,在成功识别可用小分子拮抗剂方面处于独特的地位
关键的GDF-15和GFFR结合区的知识。GFRAL拮抗剂相对于
到目前为止,在临床试验中测试的其他机制是第一次。)恶病质是可以治愈的
而不是解决恶病质和b.)一种精确的医学方法可以用来识别患者
根据他们的血浆GDF-15水平来增加疗效和应答者数量。
第一阶段的成功结果将从1-2个逆转的铅化学系列中确定
老鼠患癌症恶病质。在第二阶段拨款之前,第一阶段导联将进行优化,以提供临床
研究新药使能研究的候选人。每天一次的口试将阻止90%
GDF-15水平升高的癌症患者的GFra(<;1 ng/mL)。阻止GFAL的数量将增加
食欲,减少分解代谢,增加肌肉质量,以实现最佳的抗癌治疗和
提高存活率。
英文摘要
Project Summary
The goal of the project is to identify for the first time, a brain-penetrant small molecule antagonist against
Glial cell line-derived neurotrophic factor Family Receptor α-Like (GFRAL) for the prevention and reversal
of cancer anorexia-cachexia. Anorexia-cachexia is a debilitating, life threatening disease, associated with
pronounced loss of appetite, skeletal muscle and fat mass. Cancer anorexia-cachexia constitutes a major
unmet medical need, as 80% of patients with advanced cancers exhibit cachexia and 20% of cancer-related
mortalities are derived from cachexia rather than direct tumor burden. Patients are less tolerant to
radiotherapy, chemotherapy, pharmacotherapy and surgery. As a result, patients receive lower doses,
reduced duration of treatment or are not eligible for treatment, indirectly decreasing survival. There is
currently no approved treatment for anorexia-cachexia thus representing a high unmet medical need.
The etiology of cancer anorexia-cachexia is attributed to abnormal metabolism, induced by tumor-
derived cytokines. Precachectic and cachectic patients have elevated levels of Growth Differentiation
Factor-15 (GDF-15) which is correlated with poor survival. GDF-15 has emerged as critical factor mediating
anorexia-cachexia. Preclinically, GDF-15 causes anorexia in mice, rats and primates while blocking
endogenous GDF-15 in cancer cachexia models, prevents and reverses anorexia-cachexia with an
impressive 100% survival.
Recently, it has been identified that GDF-15 mediates its effects via GFRAL located within the
brainstem. Blocking the effect of GDF-15 via GFRAL with a small molecule versus a biologic offers the best
opportunity to access the brain and achieve sufficient concentrations to block >90% of GFRAL. BYOMass
is in a unique position for success in identifying druggable small molecule antagonists facilitated by our
knowledge of crucial GDF-15 and GFRAL binding regions. A key advantage of a GFRAL antagonist versus
other mechanisms tested to date in clinical trials, is that for the first-time a.) cachexia can be cured rather
than address symptoms of cachexia and b.) a precision medicine approach can be used to identify patients
based on their plasma GDF-15 levels to increase efficacy and the number of responders.
A successful outcome of Phase 1 will be hit identification from 1-2 lead chemical series that reverses
cancer cachexia in mice. Pending a Phase 2 grant, Phase 1 leads will be optimized to deliver a clinical
candidate for Investigational New Drug enabling studies. The once daily, oral candidate will block >90%
GFRAL in cancer patients with elevated levels of GDF-15 (<1 ng/mL). Blocking GFRAL will increase
appetite, decrease catabolism and increase muscle mass, to enable optimal anti-cancer therapy and
increase survival.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文